Mortality at day 30 · AKI
Intensive showed no clear difference in mortality at day 30 compared with less intensive continuous renal replacement therapy (CRRT) (low certainty).
1 finding from 1 review
Mortality after 30 days post‐randomisation · AKI
Intensive showed no clear difference in mortality after 30 days post‐randomisation compared with less intensive continuous renal replacement therapy (CRRT) (low certainty).
1 finding from 1 review
Patients free of RRT after discontinuing CRRT · AKI
Intensive showed no clear difference in patients free of RRT after discontinuing CRRT compared with less intensive continuous renal replacement therapy (CRRT) (low certainty).
2 findings from 1 review
Adverse events: hypophosphataemia · AKI
Intensive leads to higher adverse events: hypophosphataemia compared with less intensive continuous renal replacement therapy (CRRT) (high certainty).
1 finding from 1 review
Mortality: patients with sepsis · patients with AKI who need CRRT
Intensive showed no clear difference in mortality: patients with sepsis compared with less intensive continuous renal replacement therapy (CRRT) (low certainty).
1 finding from 1 review
Mortality: patients without sepsis · patients with AKI who need CRRT
Intensive showed no clear difference in mortality: patients without sepsis compared with less intensive continuous renal replacement therapy (CRRT) (low certainty).
1 finding from 1 review
Mortality: patients with AKI related to cardiac or general surgery · patients with AKI who need CRRT
Intensive leads to lower mortality: patients with AKI related to cardiac or general surgery compared with less intensive continuous renal replacement therapy (CRRT) (high certainty).
1 finding from 1 review
Mortality: patients with AKI not related to surgery · patients with AKI who need CRRT
Intensive showed no clear difference in mortality: patients with AKI not related to surgery compared with less intensive continuous renal replacement therapy (CRRT) (low certainty).
1 finding from 1 review
Death (all causes) · people with diabetes and kidney disease
Angiotensin receptor blockers showed no clear difference in all‐cause death Median compared with angiotensin‐converting‐enzyme inhibitors (low certainty).
1 finding from 1 review
Cardiovascular mortality · people with diabetes and kidney disease
Angiotensin receptor blockers showed no clear difference in cardiovascular death Median compared with angiotensin‐converting‐enzyme inhibitors (low certainty).
1 finding from 1 review
Doubling of SCr Median · people with diabetes and kidney disease
Angiotensin receptor blockers showed no clear difference in doubling of SCr Median compared with angiotensin‐converting‐enzyme inhibitors (low certainty).
1 finding from 1 review
Fatal or nonfatal stroke · people with diabetes and kidney disease
Angiotensin receptor blockers showed no clear difference in fatal or nonfatal stroke Median compared with angiotensin‐converting‐enzyme inhibitors (low certainty).
1 finding from 1 review
Fatal or nonfatal myocardial infarction · people with diabetes and kidney disease
Angiotensin receptor blockers showed no clear difference in fatal or nonfatal myocardial infarction Median compared with angiotensin‐converting‐enzyme inhibitors (low certainty).
1 finding from 1 review
Micro‐ to macroalbuminuria Median · people with diabetes and kidney disease
Angiotensin receptor blockers showed no clear difference in micro‐ to macroalbuminuria Median compared with angiotensin‐converting‐enzyme inhibitors (low certainty).
1 finding from 1 review
RR 0.97 [0.67, 1.42]
965 participants
Low
Micro‐ to normoalbuminuria Median · people with diabetes and kidney disease
Angiotensin receptor blockers showed no clear difference in micro‐ to normoalbuminuria Median compared with angiotensin‐converting‐enzyme inhibitors (low certainty).
1 finding from 1 review
Transplant or graft survival · pre‐existing and new‐onset diabetes in kidney transplant recipients
It is very uncertain whether more intensive changes transplant or graft survival compared with less intensive insulin therapy (very low certainty).
1 finding from 1 review
Delayed graft function · pre‐existing and new‐onset diabetes in kidney transplant recipients
It is very uncertain whether more intensive changes delayed graft function Time frame: 1 to 3 years compared with less intensive insulin therapy (very low certainty).
1 finding from 1 review
HbA1c (%) · pre‐existing and new‐onset diabetes in kidney transplant recipients
1 finding from 1 review
FBG (mmol/L) · pre‐existing and new‐onset diabetes in kidney transplant recipients
1 finding from 1 review
Kidney function markers · pre‐existing and new‐onset diabetes in kidney transplant recipients
1 finding from 1 review